Anticoagulation and Antiplatelet Therapy for Polycythemia Vera

Introduction to Antiplatelet Therapy

The European Society of Cardiology and American Heart Association recommend clopidogrel 75 mg daily as the primary alternative antiplatelet agent for patients with aspirin allergy or intolerance 1
Clopidogrel is the first-line alternative antiplatelet agent for patients who cannot tolerate aspirin, as stated by the European Society of Cardiology and American Heart Association guidelines 1

Therapeutic phlebotomy must be initiated to maintain hematocrit <45% to reduce thrombotic risk in polycythemia vera, as recommended by the Mayo Clinic Proceedings 2
Phlebotomy substantially reduces thrombosis risk in polycythemia vera, but does not eliminate it, according to the Mayo Clinic Proceedings 2
The CYTO-PV trial established hematocrit <45% as the treatment goal for polycythemia vera, as published in the Annals of Oncology 3

Warfarin (INR 2-3) can be combined with clopidogrel 75 mg daily in patients requiring both anticoagulation and antiplatelet therapy, as recommended by the European Heart Journal and Circulation 1, 4
Direct Oral Anticoagulants (DOACs) are first-line for venous thromboembolism and nonvalvular atrial fibrillation if anticoagulation is indicated, with renal function monitoring required, particularly with dabigatran, as stated by the European Heart Journal 5

Fibrate therapy (fenofibrate or gemfibrozil) should be initiated as first-line pharmacotherapy for triglycerides >500 mg/dL, as recommended by the Circulation journal 6
Therapeutic lifestyle changes, including low saturated fat, carbohydrate-controlled diet, alcohol reduction, and aerobic exercise, are essential for managing severe hypertriglyceridemia, as stated by the Circulation journal 6

Aspirin is absolutely contraindicated in patients with documented allergy, and attempting desensitization or using aspirin despite allergy risks serious hypersensitivity reactions, as warned by the Circulation journal 1, 6, 7
Antiplatelet therapy (clopidogrel) is the standard for polycythemia vera without specific anticoagulation indications, and anticoagulation with warfarin or DOACs is reserved for specific conditions, as recommended by the Mayo Clinic Proceedings and Circulation 1, 2

The American College of Physicians recommends that a hematocrit exceeding the 95th percentile for normal distribution meets criteria for suspected polycythemia vera 8, 9
A low serum erythropoietin level (specificity >90%) is highly suggestive of polycythemia vera, though sensitivity is only 70% 8, 9
Elevated neutrophils (leukocytosis) occur in 49% of polycythemia vera cases and represent a PV-related feature that strengthens diagnostic suspicion 9

The American Society of Hematology recommends that patients with polycythemia vera require therapeutic phlebotomy to maintain hematocrit <45% (reduces thrombosis risk) 10
Low-dose aspirin 81 mg once daily is recommended for all patients with polycythemia vera, unless contraindicated by bleeding risk 10
High-risk patients with polycythemia vera additionally need cytoreductive therapy, with hydroxyurea as the first-line treatment (proven thrombosis reduction) 10

The American Thoracic Society recommends that sleep apnea be treated with CPAP therapy to resolve polycythemia by eliminating nocturnal hypoxemia 11
Smoking cessation is recommended to reverse polycythemia, as carbon monoxide exposure causes real polycythemia that resolves with cessation 12, 13
Chronic lung disease should be optimized with pulmonary management, and supplemental oxygen considered 14

The American Society of Clinical Oncology recommends serial monitoring of complete blood counts and symptom assessment for patients with polycythemia vera 10
Prognosis for secondary polycythemia depends entirely on treating the underlying condition 13
Polycythemia should resolve with correction of hypoxia or removal of EPO stimulus 13, 11

During the pre-phlebotomy era, thrombosis was the major cause of death with median life expectancy less than 2 years, according to the Mayo Clinic Proceedings 15

When polycythemia is secondary to hypoxemia, symptoms of the underlying condition predominate, and major symptoms in polycythemia rubra vera relate to arterial hypertension and arterial/venous thrombosis, as reported in Stroke 16